Desmethylcitalopram is a major metabolite of the selective serotonin reuptake inhibitor (SSRI) citalopram, widely used in antidepressant therapy [, ]. Chemically, it is the N-desmethylated form of citalopram, formed by removing a methyl group from the nitrogen atom in citalopram []. Desmethylcitalopram plays a significant role in scientific research, particularly in understanding the metabolism and pharmacodynamics of citalopram, and exploring its potential impact on biological systems [].

Citalopram

Compound Description: Citalopram is a selective serotonin reuptake inhibitor (SSRI) widely prescribed for treating depression and anxiety disorders. It is a racemic mixture of (R)- and (S)-enantiomers, with the (S)-enantiomer (escitalopram) being the more pharmacologically active form. []

Relevance: Citalopram is the parent compound of desmethylcitalopram. Desmethylcitalopram is the major metabolite of citalopram, formed through N-demethylation primarily by CYP2C19 and to a lesser extent by CYP3A4 and CYP2D6. [, , , , ] Both citalopram and desmethylcitalopram contribute to the therapeutic effects of citalopram, although desmethylcitalopram is less potent. [, , ]

Didesmethylcitalopram

Compound Description: Didesmethylcitalopram is a secondary metabolite of citalopram, formed through further N-demethylation of desmethylcitalopram. [, , ] While it possesses some affinity for the serotonin transporter, its pharmacological activity is significantly lower than citalopram and desmethylcitalopram. []

Relevance: Didesmethylcitalopram is a downstream metabolite of desmethylcitalopram in the citalopram metabolic pathway. [, , , ] The formation of didesmethylcitalopram from desmethylcitalopram is primarily mediated by CYP2D6. [, ]

Escitalopram

Compound Description: Escitalopram is the (S)-enantiomer of citalopram and is marketed as a separate antidepressant medication. It is a more potent and selective SSRI compared to the racemic citalopram. [, , ]

Relevance: Escitalopram shares a close structural relationship with desmethylcitalopram as it is the active enantiomer of citalopram, from which desmethylcitalopram is metabolized. Studies have investigated the pharmacokinetics of escitalopram and its metabolites, S-desmethylcitalopram and S-didesmethylcitalopram, in relation to genetic polymorphisms. [, , ]

Nortriptyline

Compound Description: Nortriptyline is a tricyclic antidepressant that acts as a serotonin-norepinephrine reuptake inhibitor. []

Relevance: Nortriptyline was investigated in a study alongside citalopram and their respective metabolites (nortriptyline, desmethylcitalopram, and didesmethylcitalopram) to assess drug distribution patterns in decomposed skeletal tissues. [] The study aimed to discriminate between different drug exposure patterns using bone samples.

Fluoxetine

Compound Description: Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) commonly used to treat depression. [, , ]

Relevance: Fluoxetine, along with citalopram, is a commonly prescribed antidepressant. Both drugs and their active metabolites, including desmethylcitalopram, have been included in various analytical methods for quantification in biological samples. [, , ] These methods aim to assess drug concentrations in cases of overdose, therapeutic drug monitoring, or forensic investigations.

Norfluoxetine

Compound Description: Norfluoxetine is the major active metabolite of fluoxetine, also exhibiting serotonin reuptake inhibition. [, ]

Relevance: Norfluoxetine, similar to desmethylcitalopram, is an active metabolite of an SSRI. Both metabolites, alongside desmethylcitalopram and desvenlafaxine, were studied for their ability to inhibit the serotonin transporter, demonstrating their contribution to the pharmacological effects of their parent compounds. [] Furthermore, norfluoxetine, like desmethylcitalopram, has been included in studies assessing P-glycoprotein inhibition by antidepressants, highlighting a potential area of drug interaction. []

Sertraline

Compound Description: Sertraline is a selective serotonin reuptake inhibitor (SSRI) used in treating depression and anxiety disorders. [, , ]

Relevance: Sertraline, alongside citalopram, represents a commonly prescribed SSRI. Studies have developed and validated analytical methods for the simultaneous quantification of various antidepressants, including citalopram, desmethylcitalopram, and sertraline, in biological samples. [, ] These methods facilitate the monitoring of therapeutic drug levels and aid in forensic investigations.

Desmethylsertraline

Compound Description: Desmethylsertraline is the major active metabolite of sertraline, also displaying serotonin reuptake inhibitory properties. [, , ]

Relevance: Desmethylsertraline is the primary metabolite of sertraline, similar to the relationship between citalopram and desmethylcitalopram. [] Research indicates that desmethylsertraline, like desmethylcitalopram, can inhibit the serotonin transporter, highlighting its contribution to the overall pharmacological effects observed with sertraline treatment. [] Furthermore, both desmethylsertraline and desmethylcitalopram are included in studies investigating the inhibitory effects of antidepressants on P-glycoprotein, indicating a potential for drug interactions. []

Venlafaxine

Compound Description: Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for depression and anxiety disorders. [, , , , ]

Relevance: Venlafaxine, like citalopram, is frequently prescribed for treating depression. Various studies have developed and validated analytical methods for the simultaneous quantification of multiple antidepressants, including citalopram, desmethylcitalopram, and venlafaxine, in biological matrices such as plasma. [, , ] These methods are crucial for therapeutic drug monitoring and forensic toxicology investigations.

Desmethylvenlafaxine

Compound Description: Desmethylvenlafaxine is the major active metabolite of venlafaxine, demonstrating comparable potency as a serotonin-norepinephrine reuptake inhibitor. [, , , , ]

Relevance: Desmethylvenlafaxine is the primary active metabolite of venlafaxine, much like the relationship between citalopram and desmethylcitalopram. Both metabolites, desmethylvenlafaxine and desmethylcitalopram, have been investigated for their inhibitory effects on the serotonin transporter, demonstrating their contribution to the pharmacological action of their respective parent drugs. [] Additionally, both metabolites are included in analytical methods developed for the simultaneous quantification of various antidepressants and their metabolites, highlighting their importance in therapeutic drug monitoring and forensic toxicology. [, , , ]

Paroxetine

Compound Description: Paroxetine is a selective serotonin reuptake inhibitor (SSRI) commonly prescribed for treating depression, anxiety disorders, and obsessive-compulsive disorder. [, , , , ]

Relevance: Paroxetine, similar to citalopram, is a widely used SSRI. Analytical methods capable of quantifying citalopram, desmethylcitalopram, and paroxetine simultaneously in biological samples have been developed and validated. [, , , ] These methods aid in the monitoring of therapeutic drug levels, management of overdoses, and forensic investigations.

Fluvoxamine

Compound Description: Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) primarily used for treating obsessive-compulsive disorder and sometimes for depression and anxiety disorders. [, , ]

Relevance: Fluvoxamine, like citalopram, is a commonly prescribed SSRI. Studies have developed analytical methods capable of quantifying citalopram, desmethylcitalopram, and fluvoxamine simultaneously in biological samples. [, , ] These methods enable the monitoring of therapeutic drug levels, management of overdoses, and aid in forensic investigations.

Mirtazapine

Compound Description: Mirtazapine is a tetracyclic antidepressant that acts as a noradrenergic and specific serotonergic antidepressant (NaSSA), enhancing noradrenergic and serotonergic neurotransmission. [, , ]

Relevance: Mirtazapine, alongside citalopram, is a commonly prescribed antidepressant. Researchers have developed analytical methods capable of quantifying citalopram, desmethylcitalopram, and mirtazapine concurrently in biological samples. [, , ] These methods facilitate therapeutic drug monitoring, overdose management, and forensic toxicological analyses.

Milnacipram

Compound Description: Milnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) primarily used to treat fibromyalgia and major depressive disorder. [, , ]

Relevance: Milnacipran, similar to citalopram, is an antidepressant drug. Studies have developed and validated analytical methods for the simultaneous quantification of various antidepressants, including citalopram, desmethylcitalopram, and milnacipran, in biological samples. [, , ] These methods are crucial for therapeutic drug monitoring and forensic toxicological analyses.

Duloxetine

Compound Description: Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) commonly prescribed for treating major depressive disorder, generalized anxiety disorder, and certain pain conditions. []

Relevance: Duloxetine, similar to citalopram, is a commonly prescribed antidepressant. Researchers have developed analytical methods for quantifying duloxetine along with other antidepressants, including citalopram and desmethylcitalopram, in biological samples. [] These methods are essential for therapeutic drug monitoring and forensic toxicology.

Amitriptyline

Compound Description: Amitriptyline is a tricyclic antidepressant (TCA) that acts as a serotonin-norepinephrine reuptake inhibitor. It is frequently used for managing major depressive disorder, neuropathic pain, and migraine prophylaxis. []

Relevance: Amitriptyline was studied alongside citalopram and their respective metabolites (nortriptyline, desmethylcitalopram, and didesmethylcitalopram) to evaluate their distribution patterns in decomposed skeletal tissues. [] The study aimed to discriminate between different drug exposure patterns by analyzing drug concentrations in bone samples.

Clomipramine

Compound Description: Clomipramine is a tricyclic antidepressant (TCA) classified as a serotonin-norepinephrine reuptake inhibitor. It is primarily prescribed for obsessive-compulsive disorder and occasionally for depression, panic disorder, and other conditions. [, , ]

Relevance: Clomipramine, like citalopram, is an antidepressant medication. Research has demonstrated that concomitant treatment with clomipramine can significantly increase serum concentrations of both citalopram and desmethylcitalopram, suggesting a potential drug interaction. [] This interaction highlights the importance of considering co-administered medications when prescribing and monitoring citalopram therapy.

Desipramine

Compound Description: Desipramine is a tricyclic antidepressant (TCA) primarily acting as a norepinephrine reuptake inhibitor, with weaker effects on serotonin reuptake. It is often prescribed for treating depression and, less commonly, for nerve pain and bedwetting. []

Relevance: Desipramine is a tricyclic antidepressant that shares metabolic pathways with citalopram. Citalopram’s primary metabolite, desmethylcitalopram, can inhibit the CYP2D6 enzyme, which is also responsible for metabolizing desipramine to its active metabolite, 2-hydroxydesipramine. [] This interaction can lead to increased levels of desipramine and potentially enhance its effects or side effects.

Imipramine

Compound Description: Imipramine is a tricyclic antidepressant (TCA) classified as a serotonin-norepinephrine reuptake inhibitor. It is widely used to manage depression, anxiety disorders, and bedwetting in children. [, , ]

Relevance: Imipramine, similar to citalopram, is a commonly used antidepressant. Studies have examined potential drug interactions between citalopram and imipramine, focusing on their effects on shared metabolic pathways. Citalopram, specifically its metabolite desmethylcitalopram, can inhibit the metabolism of imipramine, potentially leading to altered drug levels and clinical effects. []

Levomepromazine

Compound Description: Levomepromazine, also known as methotrimeprazine, is a phenothiazine antipsychotic primarily used for treating schizophrenia, agitation, and insomnia. It exhibits strong antidopaminergic and antihistaminergic properties. [, ]

Relevance: Levomepromazine, being a potent inhibitor of the CYP2D6 enzyme, was studied for its potential interaction with citalopram. Research suggests that levomepromazine can increase the steady-state levels of desmethylcitalopram, likely due to the inhibition of CYP2D6-mediated metabolism. [] This interaction highlights the importance of considering CYP2D6-mediated metabolism when co-administering these drugs.

Desmethylcitalopram is derived from the metabolic process of citalopram. It belongs to the class of compounds known as SSRIs, which are characterized by their ability to selectively inhibit the reuptake of serotonin in the synaptic cleft, enhancing serotonergic neurotransmission. Its chemical structure allows it to interact with serotonin transporters and various neurotransmitter receptors, contributing to its antidepressant effects.

The synthesis of desmethylcitalopram has been explored through various methods. A notable process involves the demethylation of citalopram, which can be achieved using different reagents and conditions.

Methods and Technical Details

One effective synthesis method includes:

1. Dissolution: Citalopram is dissolved in isopropyl alcohol.
2. Reaction with Acid: The solution is treated with di-p-toluoyl-L-tartaric acid.
3. Separation: The resultant mixture undergoes phase separation using dichloromethane and water.
4. Demethylation: Formaldehyde and formic acid are added to facilitate demethylation under controlled temperature conditions.
5. Isolation: The product is extracted, washed, and dried to yield desmethylcitalopram.

This method has shown a yield of approximately 76.55%, demonstrating its efficiency in producing the desired compound from citalopram  .

Desmethylcitalopram has a specific molecular structure that contributes to its pharmacological properties.

Structure and Data

• Chemical Formula: C_{20}H_{22}N_{2}O
• Molecular Weight: 306.40 g/mol
• Structural Features: The compound consists of a bicyclic structure with a nitrogen-containing ring, which is crucial for its interaction with serotonin transporters.

The stereochemistry of desmethylcitalopram also plays a significant role in its activity, with specific enantiomers exhibiting different potencies  .

Desmethylcitalopram can undergo various chemical reactions that may alter its structure and activity.

Reactions and Technical Details

1. N-Demethylation: This reaction converts citalopram into desmethylcitalopram, primarily facilitated by metabolic enzymes such as cytochrome P450.
2. Further Demethylation: Desmethylcitalopram can be further demethylated to form didesmethylcitalopram, which has been shown to exhibit higher inhibitory efficacy on serotonin reuptake compared to its precursors.
3. Reactivity with Acids: The presence of functional groups allows for reactions with acids or bases that can modify its solubility and bioavailability  .

The mechanism by which desmethylcitalopram exerts its effects involves several biochemical pathways.

Process and Data

Desmethylcitalopram primarily acts as an inhibitor of the serotonin transporter (SERT). By binding to this transporter, it prevents the reuptake of serotonin from the synaptic cleft back into presynaptic neurons. This results in increased serotonin availability in the synaptic space, enhancing serotonergic neurotransmission and contributing to antidepressant effects.

Additionally, studies have shown that desmethylcitalopram interacts with various neurotransmitter receptors, influencing mood and anxiety levels  .

Understanding the physical and chemical properties of desmethylcitalopram is essential for its application in pharmacology.

Physical Properties

• Appearance: Typically exists as a white crystalline powder.
• Solubility: Soluble in organic solvents like methanol and dichloromethane but poorly soluble in water.

Chemical Properties

• Stability: Generally stable under normal storage conditions but sensitive to light and moisture.
• pH Sensitivity: Exhibits changes in solubility depending on pH levels, which can affect its bioavailability  .

Desmethylcitalopram has several scientific applications beyond its role as a metabolite.

Scientific Uses

1. Pharmacological Research: Used to study the pharmacokinetics and dynamics of SSRIs.
2. Clinical Studies: Investigated for its potential efficacy as an antidepressant agent on its own or in combination with other drugs.
3. Biochemical Assays: Employed in assays to evaluate serotonin transporter activity and receptor binding profiles  .

Structural Characterization and Stereochemical Properties

Desmethylcitalopram (DCT), systematically named 1-(4-fluorophenyl)-1-[3-(methylamino)propyl]-1,3-dihydro-2-benzofuran-5-carbonitrile, is a monodesmethyl metabolite of the antidepressant drugs citalopram (racemic) and escitalopram (S-enantiomer). Its molecular formula is C₁₉H₁₉FN₂O, with a molar mass of 310.37 g/mol [3] [9]. The compound features a chiral center at the carbon adjacent to the fluorophenyl group, generating R– and S-enantiomers. Unlike the parent drug citalopram—a racemic mixture—desmethylcitalopram retains the stereochemical configuration of its precursor during biosynthesis. The S-enantiomer (desmethylescitalopram) is pharmacologically relevant due to its affinity for the serotonin transporter (SERT) [3] [7].

Key structural properties include:

• A benzofuran core linked to a fluorophenyl group.
• A nitrile substituent at the 5-position of the benzofuran ring.
• A methylaminopropyl side chain replacing the dimethylaminopropyl group in citalopram [9].

• Table 1: Structural and Physicochemical Properties of Desmethylcitalopram
  

  Property	Value
  Molecular Formula	C₁₉H₁₉FN₂O
  Molar Mass	310.37 g/mol
  Chiral Centers	1
  logP (Predicted)	3.24
  Hydrogen Bond Acceptors	3
  Hydrogen Bond Donors	1
  Topological Polar Surface Area	45.05 Ų	[9]

Metabolic Pathways: N-Demethylation of Citalopram and Escitalopram

Desmethylcitalopram is primarily biosynthesized via N-demethylation of citalopram or escitalopram in the liver. This metabolic pathway proceeds in two sequential phases:

• Initial Demethylation: Citalopram (C₁₉H₂₁FN₂O) loses one methyl group from its dimethylaminopropyl chain, forming desmethylcitalopram (DCT, C₁₉H₁₉FN₂O) [3] [5].
• Secondary Demethylation: DCT undergoes further N-demethylation to form didesmethylcitalopram (DDCT, C₁₈H₁₇FN₂O) [6].

DCT accumulates significantly in plasma, reaching ~30–50% of parent drug concentrations at steady state in humans. In contrast, DDCT concentrations remain low due to rapid clearance [6] [10]. Both enantiomers of citalopram (R– and S-CT) are metabolized to their corresponding desmethyl enantiomers, though S-citalopram (escitalopram) is demethylated more efficiently than R-citalopram [6] [7].

Enzymatic Mechanisms in Hepatic Biotransformation

The N-demethylation of citalopram to DCT is catalyzed by hepatic cytochrome P450 (CYP) enzymes via oxidative dealkylation. The mechanism involves:

• Hydroxylation: CYP isoforms oxidize a methyl group in citalopram’s dimethylamino moiety to form a carbinolamine intermediate.
• Fragmentation: The unstable intermediate decomposes spontaneously, releasing formaldehyde and yielding desmethylcitalopram [5] [8].

In vitro studies using human liver microsomes demonstrate saturable kinetics for this reaction, with a mean Kₘ (Michaelis constant) of 174 ± 12 μM for racemic citalopram [5]. DCT formation follows classic Michaelis-Menten kinetics, indicating single-enzyme dominance in the metabolic pathway [5].

Role of Cytochrome P450 Isoforms (CYP2C19, CYP3A4, CYP2D6)

Three CYP isoforms drive desmethylcitalopram biosynthesis, with distinct hierarchical contributions:

CYP2C19

• Primary Role: Catalyzes the initial N-demethylation of citalopram to DCT. Genetic polymorphisms significantly impact DCT formation. Poor metabolizers (PMs) with CYP2C19 loss-of-function alleles (e.g., 2/2, 2/3, 3/3) exhibit 60–80% higher plasma S-citalopram and 40% lower S-DCT levels compared to extensive metabolizers (EMs) [2] [6] [10].
• In vitro Contribution: Accounts for ~36–52% of total DCT formation at therapeutic citalopram concentrations [5].

CYP3A4

• Secondary Role: Supports N-demethylation, particularly when CYP2C19 activity is low. Contributes ~35% to total DCT formation in vitro [5].
• Kinetics: Exhibits lower affinity (Kₘ = ~250 μM) but high capacity for citalopram metabolism [5] [8].

CYP2D6

• Minor Role: Primarily converts DCT to didesmethylcitalopram (DDCT). Its contribution to initial demethylation is negligible (<5%) [5] [6].
• Genetic Impact: Poor metabolizers show elevated DCT plasma levels due to impaired DDCT formation [10].
• Table 2: CYP Isoform Contributions to Desmethylcitalopram Formation
  

  CYP Isoform	Reaction Catalyzed	Contribution to DCT Formation	Impact of Genetic Polymorphism
  CYP2C19	CT → DCT	36–52%	PMs: ↑ CT, ↓ DCT plasma levels
  CYP3A4	CT → DCT	~35%	Inducible (e.g., by rifampicin)
  CYP2D6	DCT → DDCT	<5% (for CT→DCT)	PMs: ↑ DCT accumulation	[2] [5] [6]

Stereoselectivity in Metabolism

CYP2C19 preferentially demethylates S-citalopram over R-citalopram, leading to higher plasma concentrations of R-DCT relative to S-DCT. This stereoselectivity results in an S/R ratio of DCT <1.0 in extensive metabolizers, contrasting with the S/R ratio of citalopram (>1.0) [6] [7].

Pharmacological Implications

As an active metabolite, DCT inhibits serotonin reuptake with ~50% lower potency than S-citalopram but contributes to overall antidepressant effects during therapy. Its plasma concentrations correlate with CYP-mediated drug interactions (e.g., fluvoxamine coadministration inhibits CYP2C19, increasing CT levels) [3] [5] [8].